Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. WuXi Biologics (Cayman) Inc.
  6. News
  7. Summary
    2269   KYG970081173

WUXI BIOLOGICS (CAYMAN) INC.

(2269)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

WuXi Biologics Announces Completion of GMP Production At 24,000L Line of Its Drug Substance Facility MFG5

11/22/2021 | 07:40pm EST

WuXi Biologics announced that it has successfully completed the first GMP production at the new 24,000L line of its drug substance facility MFG5. This follows the initial GMP operations of the 36,000L biomanufacturing line of MFG5 this February. With its total 60,000L capacity, MFG5 will further support the growing demand for manufacture of late-phase and commercial projects across multiple modalities, such as monoclonal antibodies, bispecifics and fusion proteins. As a result, there is a total of approximately 150,000L biomanfacturing capacity at WuXi Biologics, which makes the company holding Top 5 capacity in the global CDMOs. The new 24,000L line utilizes the scale-out strategy combining twelve 2000L single-use bioreactors to enable the various production processes including fed-batch, perfusion and CFB at different scales, ranging from 2,000L to 12,000L. In addition, the implementation of WuXiUP continuous downstream technology in the 24,000L line for commercial production will allow MFG5 to increase productivity and reduce Cost of Goods Sold.


ę S&P Capital IQ 2021
All news about WUXI BIOLOGICS (CAYMAN) INC.
01/26Hong Kong shares end marginally higher ahead of Fed policy update
RE
01/18WUXI BIOLOGICS CAYMAN : Completes GMP Inspection by South Korea's Ministry of Food and Dru..
PU
01/12WUXI BIOLOGICS CAYMAN : 40th Annual J.P. Morgan Healthcare Conference Presentation (in PDF..
PU
01/11Hong Kong shares close unchanged; Fed policy in focus
RE
01/11China stocks fall as virus worries, Fed rate hike bets weigh; Hong Kong up
RE
01/06WUXI BIOLOGICS CAYMAN : Vaccines and BravoBio Sign Letter of Intent for Long-Term Collabor..
PU
01/05China stocks fall after hawkish Fed minutes; property, consumption drop
RE
01/05Wuxi Biologics Repurchases Nearly $503 Million Worth of Shares; Shares Fall 7%
MT
2021Hong Kong shares inch up in thin trade, healthcare jumps
RE
2021WUXI BIOLOGICS CAYMAN : and ImmuneOncia Sign MOU for Development and Manufacturing of Anti..
PU
More news
Analyst Recommendations on WUXI BIOLOGICS (CAYMAN) INC.
More recommendations
Financials
Sales 2021 9 752 M 1 535 M 1 535 M
Net income 2021 3 040 M 478 M 478 M
Net cash 2021 5 598 M 881 M 881 M
P/E ratio 2021 87,4x
Yield 2021 -
Capitalization 266 B 41 757 M 41 845 M
EV / Sales 2021 26,7x
EV / Sales 2022 18,2x
Nbr of Employees 7 686
Free-Float -
Chart WUXI BIOLOGICS (CAYMAN) INC.
Duration : Period :
WuXi Biologics (Cayman) Inc. Technical Analysis Chart | 2269 | KYG970081173 | MarketScreener
Technical analysis trends WUXI BIOLOGICS (CAYMAN) INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 63,10 CNY
Average target price 126,46 CNY
Spread / Average Target 100%
EPS Revisions
Managers and Directors
Zhi Sheng Chen Director
Ming Tu Chief Financial Officer & Executive Vice President
Ge Li Non-Executive Chairman
Weichang Zhou Chief Technology Officer & Executive Director
William Robert Keller Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
WUXI BIOLOGICS (CAYMAN) INC.-16.59%41 757
CSL LIMITED-14.20%84 148
ALEXION PHARMACEUTICALS, INC.0.00%40 336
SAMSUNG BIOLOGICS CO.,LTD.-21.15%39 159
BIOGEN INC.-8.74%32 161
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-13.07%27 227